Clinical trials: Symptom
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma
- Trial name
- SHARON (NCT04150042)
- Testing
- Melphalan, BCNU, Vitamin B12B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- General Oncology, Inc.
Pain
To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery
The objective of this study is to evaluate the safety and efficacy of acetaminophen 650 mg and acetaminophen 1000 mg in dental surgery.
- Trial name
- NCT01115673
- Testing
- Acetaminophen
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Menopause, Menopausal Symptoms
Effect of HIFAS MENOPAUSE on Quality of Life in Postmenopausal Women
This single-center, single-group, open-label study evaluated changes in menopause-related quality of life and menopausal symptoms in postmenopausal women aged 40 to 60 years after 24 weeks of treatment with HIFAS MENOPAUSE.
- Trial name
- NCT07752641
- Testing
- HIFAS MENOPAUSE
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hifas da Terra S.L.
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Breast Cancer
PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy
The purpose of this clinical study is to quantify the difference in thermal injury depth at the surgical margin in breast lumpectomy specimens excised with the PlasmaBlade; to subjectively assess histopathologic sample quality…
- Trial name
- PRECISE (NCT00960154)
- Testing
- PEAK PlasmaBlade, Traditional Electrosurgery with scalpel
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic Surgical Technologies
Atrial Arrhythmia, Atrial Fibrillation
VOLT CE Mark Study
This clinical investigation is intended to demonstrate safety and effectiveness of the Volt™ Pulsed Field Ablation (PFA) Catheter Sensor Enabled™, the Volt™ PFA Generator, Agilis™ NxT Steerable Introducer Dual-Reach™, and EnSite™…
- Conditions
- Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
- Trial name
- NCT06106594
- Testing
- Pulsed Field Ablation
- Where
- 11 sites in Australia, Austria and 5 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Advanced Parkinson's Disease
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
- Trial name
- NCT00357994
- Testing
- Levodopa carbidopa intestinal gel (LCIG), Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, CADD-Legacy® 1400 ambulatory infusion pump
- Where
- 15 sites in United States, Germany
- Volunteers
- 36 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Ventilator Associated Pneumonia
Optimal Endotracheal Cuff Pressure During Hospitalization in Intensive Care Units Using AnapnoGuard 100 System
Hospitech Respiration Ltd has developed the AnapnoGuard system, an innovative system intended to enhance optimal endotracheal tube (ETT) cuff inflation, by monitoring carbon dioxide (CO2) in upper airways of mechanically…
- Trial name
- NCT01188122
- Testing
- AnapnoGuard 100
- Where
- Romania
- Volunteers
- 12 people
- Sponsor
- Hospitech Respiration
Spondylitis, Ankylosing, Pain
An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)
The purpose of the study is to investigate the clinical benefit of tramadol/acetaminophen versus non-steroidal anti-inflammatory drugs (NSAID) (diclofenac 50 milligram [mg]) in the treatment of pain in participants with…
- Trial name
- NCT00766402
- Testing
- Tramadol /acetaminophen, Diclofenac
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Overweight, Obesity
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity.
- Trial name
- NCT07437079
- Testing
- NNC6989-0001
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Safety and Performance of the CAVU Medical, Inc. Attune Tubing Study
The objectives of this clinical research project are to demonstrate the safety and feasibility of CAVU Medical, Inc.'s Attune Device.
- Trial name
- NCT01422941
- Testing
- CAVU Attune Device
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Cavu Medical, Inc.
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- 3DUTCH (NCT02817594)
- Where
- 9 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- AbbVie
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Breast Cancer
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before.
- Trial name
- NCT03734029
- Testing
- Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin
- Where
- 208 sites in United States, Austria and 18 more
- Volunteers
- 557 people
- Sponsor
- Daiichi Sankyo
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder
This study will demonstrate the efficacy of agomelatine (AGO178) 25 mg and 50 mg in the prevention of relapse in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT00467402
- Testing
- agomelatine
- Where
- 78 sites in United States
- Volunteers
- 644 people
- Sponsor
- Novartis
Chronic Low-back Pain, Anxiety
EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain
The aim of this randomized controlled trial (RCT) is to assess outcomes for virtual reality therapy (including pain intensity, pain interference, anxiety, depression, physical function, sleep, behavioral skills development…
- Conditions
- Chronic Low-back Pain, Anxiety, Depression
- Trial name
- AVR_HEOR (NCT05263037)
- Testing
- EaseVRx
- Where
- United States
- Volunteers
- 1,093 people
- Sponsor
- AppliedVR Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® Dosing Optimization Study
MKC-TI-191 is a Phase 4, single-arm, multicenter, proof-of-concept clinical trial evaluating the efficacy and safety of Afrezza, administered according to the current Afrezza prescribing information (PI) compared to a titrated…
- Trial name
- DOS (NCT04849845)
- Testing
- Afrezza Dose 1, Afrezza Dose 2
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mannkind Corporation
Epworth Sleepiness Scale, Glycemic Control
LAP-BAND Observational Cohort
To prospectively observe the association of the LAP-BAND procedure on quality of life, anthropometric, metabolic and biochemical parameters in morbidly obese patients when performed by experienced US surgeons.
- Conditions
- Epworth Sleepiness Scale, Glycemic Control, Liver Function, Inflammation
- Trial name
- NCT00283972
- Testing
- LAP-BAND System
- Volunteers
- 240 people
- Sponsor
- Inamed
Blood Sugar; High, Overweight and Obesity
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1
- Trial name
- RCT (NCT07141472)
- Testing
- GB
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Lawry Han
Chronic Hepatitis B Infection, Chronic Hepatitis D Infection
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Primary objective: To evaluate the safety and tolerability of sequential administration of P1101 and anti-PD1 in patient with chronic hepatitis B or D infection Secondary objectives: 1.
- Trial name
- NCT04638439
- Testing
- P1101 + Nivolumab + Entecavir
- Where
- 5 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- PharmaEssentia
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.